Compare Sanofi SA (SNY) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Sanofi SA trades at $43.6 (market cap $104.30B), while YieldMax Universe Fund of Option Income ETFs trades at $7.65. The key difference: Sanofi SA pays a 5.55% dividend while YieldMax Universe Fund of Option Income ETFs pays none, and Sanofi SA is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| SNY | YMAX | |
|---|---|---|
Market Cap | $104.30B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $52.34 | $13.26 |
52-Week Low | $41.33 | $7.27 |
Enterprise Value | $124.19B | — |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
YMAX trades at $7.63, down 1.04% in the past 24 hours, with technical indicators showing a bullish overall signal but bearish moving averages. The fund has announced consistent weekly dividend distributions, though recent news highlights concerns over fee structures impacting payouts. Key support is at $7, with resistance at $8.
The outlook for YMAX hinges on its ability to sustain dividend yields amid fee pressures; opportunities include high income generation, but risks involve cost inefficiencies and market volatility. Analyst sentiment is mixed, balancing yield appeal against structural drawbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
